Search

Displaying results 5621 - 5630 of 8974 in total
  1. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.

  2. Drug

    IP501

    go.drugbank.com/drugs/DB06450
    Experimental

    IP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis. … The compound was developed by Indevus Pharmaceuticals.

  3. Drug

    Chamaecyparis obtusa leaf

    go.drugbank.com/drugs/DB14686
    Investigational

    Mixtures: Rhodd Ato Repair Body So Ap
  4. Drug

    Willow bark

    go.drugbank.com/drugs/DB14691
    Approved

    Mixtures: Miller's Formula No. 1
  5. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).

  6. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  7. Drug

    Holcus lanatus pollen

    go.drugbank.com/drugs/DB10395
    Approved

    Holcus lanatus pollen is the pollen of the Holcus lanatus plant. Holcus lanatus pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized Grasses
  8. Drug

    Arrhenatherum elatius pollen

    go.drugbank.com/drugs/DB10879
    Approved

    Arrhenatherum elatius pollen is the pollen of the Arrhenatherum elatius plant. Arrhenatherum elatius pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized Grasses
  9. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  10. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation … It is being developed by Amira.